SCHEMBL5555013

SCHEMBL5555013

c1ccc(-c2cccc(-c3cncc4sccc34)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 5/20 0.57
CSNK1D P48730 5/20 0.44
GSK3A P49840 5/20 0.44
GSK3B P49841 5/20 0.44
DYRK1A Q13627 5/20 0.44
AURKB Q96GD4 5/20 0.44
PLK4 O00444 4/20 0.44
AURKA O14965 4/20 0.44
DAPK3 O43293 4/20 0.44
CHEK2 O96017 4/20 0.44
CDK1 P06493 4/20 0.44
PIM1 P11309 4/20 0.44
CDK2 P24941 4/20 0.44
MAPK9 P45984 4/20 0.44
CSNK2A1 P68400 4/20 0.44
PLK3 Q9H4B4 4/20 0.44
PIM2 Q9P1W9 4/20 0.44
PRKACA P17612 3/20 0.44
RPS6KA3 P51812 3/20 0.44
SGK2 Q9HBY8 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6855709 0.89 PLK4 (0.50) MAP3K8CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL5555935 0.73 MAP3K8 (1.00) MAP3K8CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL9749622 0.72 ALOX5 (0.46) CSNK2A1ADRA2AADRA2BRORBDHODH
SCHEMBL19769127 0.71 MAP3K8 (0.81) MAP3K8CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL19769129 0.71 MAP3K8 (1.00) MAP3K8CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL24105873 0.71 MAP3K8 (0.48) MAP3K8CYP11B1CYP11B2
SCHEMBL7059724 0.70 PTGS1 (0.43) MAP3K8CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL5550198 0.70 MAP3K8 (0.57) MAP3K8PIM1MAP2K1ICAM1SELE
SCHEMBL12076750 0.69 MKNK1 (0.57) CYP11B1CYP11B2
SCHEMBL13021732 0.69 MAP3K8 (0.47) MAP3K8CSNK1DGSK3AGSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 MAP3K8 13/4885CSNK1D 151/4885GSK3A 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.